Spots Global Cancer Trial Database for vegfr inhibitor
Every month we try and update this database with for vegfr inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer | NCT00389441 | Thyroid Neoplas... | AG-013736 | 18 Years - | Pfizer | |
| Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... | NCT02484404 | Colorectal Neop... Breast Neoplasm... | Olaparib Cediranib Durvalumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer | NCT00389441 | Thyroid Neoplas... | AG-013736 | 18 Years - | Pfizer | |
| A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations | NCT02824458 | EGFR Tyrosine K... | Apatinib Gefitinib Placebo | 18 Years - 70 Years | Sun Yat-sen University | |
| A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients | NCT03075462 | Ovarian Cancer Triple Negative... | Fluzoparib Apatinib | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients | NCT03026881 | Recurrent and M... | Fluzoparib Apatinib Paclitaxel | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial | NCT01160926 | Rectal Cancer | AZD6244 Cediranib (AZD2... | 18 Years - | The Christie NHS Foundation Trust | |
| A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients | NCT03026881 | Recurrent and M... | Fluzoparib Apatinib Paclitaxel | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) | NCT01235962 | Renal Cell Carc... Cancer | pazopanib placebo pazopanib placebo | 18 Years - | Novartis | |
| Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... | NCT02484404 | Colorectal Neop... Breast Neoplasm... | Olaparib Cediranib Durvalumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... | NCT02484404 | Colorectal Neop... Breast Neoplasm... | Olaparib Cediranib Durvalumab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) | NCT01235962 | Renal Cell Carc... Cancer | pazopanib placebo pazopanib placebo | 18 Years - | Novartis | |
| A Study of Fluzoparib Given in Combination With Apatinib and Paclitaxel in Gastric Cancer Patients | NCT03026881 | Recurrent and M... | Fluzoparib Apatinib Paclitaxel | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
